Day 0 | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | |
---|---|---|---|---|---|---|---|
Cycle 1–3 (1 cycle = 2 weeks) | |||||||
- Rituximab 500 mg/m2 i.v.* | x | ||||||
- MTX 3000–5000 mg/m2 i.v. | x | ||||||
- Ifosfamide 800 mg/m2 i.v. | x | x | x | ||||
- Liposomal AraC 50 mg i.th.** | x | ||||||
Cycle 4 + 6 (1 cycle = 3 weeks) | |||||||
- Cytarabine 3000 mg/m2 i.v | x | x | |||||
- Liposomal AraC 50 mg i.th.** | x | ||||||
- MTX 2,5 mg + prednisolone 3 mg intraventricular (patients < 65 ys)* | x | x | x | ||||
- AraC 10 mg intraventricular (patients < 65 ys)* | x | ||||||
Cycle 5 (1 cycle = 2 weeks) | |||||||
- MTX 3000–5000 mg/m2 i.v. | x | ||||||
- Ifosfamide i.v. 800 mg/m2 i.v. | x | x | x | ||||
- Liposomal AraC 50 mg i.th.** | x | ||||||
- MTX 2,5 mg + prednisolone 3 mg intraventricular (patients < 65 ys)* | x | x | x | ||||
- AraC10 mg intraventricular (patients < 65 ys)* | x | ||||||
Cycle 5 was repeated for patients < 65 ys |